Occupational exposure to endocrine disruptors and lymphoma risk in a multi-centric European study.
BACKGROUND
Incidence rates of lymphoma are usually higher in men than in women, and oestrogens may protect against lymphoma.


METHODS
We evaluated occupational exposure to endocrine disrupting chemicals (EDCs) among 2457 controls and 2178 incident lymphoma cases and subtypes from the European Epilymph study.


RESULTS
Over 30 years of exposure to EDCs compared to no exposure was associated with a 24% increased risk of mature B-cell neoplasms (P-trend=0.02). Associations were observed among men, but not women.


CONCLUSIONS
Prolonged occupational exposure to endocrine disruptors seems to be moderately associated with some lymphoma subtypes.
1] Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, 08908 Barcelona, Spain [2] Department of Medicine, University of Barcelona, 08036 Barcelona, Spain [3] CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
L
L
Costas
Department of Epidemiology, Biostatistics and Occupational Health, Faculty of Medicine, McGill University, Montréal, QC, Canada H3A 1A2.
C
C
Infante-Rivard
1] CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain [2] Netherlands Institute for Health Services Research (NIVEL), 3500 Utrecht, The Netherlands [3] Centre for Research in Environmental Epidemiology (CREAL), 08003 Barcelona, Spain [4] Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.
J-P
JP
Zock
Centre for Human Exposure Science (CHES), Institute of Occupational Medicine, EH14 4AP Edinburgh, UK.
M
M
Van Tongeren
Tisch Cancer Institute and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, 10029 NY, USA.
P
P
Boffetta
Centre de Recherche, CHU Sainte-Justine, Montréal, QC, Canada H3T 1C4.
A
A
Cusson
Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, 08908 Barcelona, Spain.
C
C
Robles
1] Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, 08908 Barcelona, Spain [2] CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
D
D
Casabonne
1] Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, 08908 Barcelona, Spain [2] CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
Y
Y
Benavente
Division of Cancer Epidemiology, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
N
N
Becker
IARC, International Agency for Research on Cancer, 69372 Lyon, France.
P
P
Brennan
Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute and MF MU, 65653 Brno, Czech Republic.
L
L
Foretova
Biological Hematology Unit, CRB Ferdinand Cabanne, Universitary Hospital of Dijon and EA4184, University of Burgundy, EA 4184 Dijon, France.
M
M
Maynadié
Public Health University College, Dublin, Ireland.
A
A
Staines
Centre of Chronic Immunodeficiency, Molecular Epidemiology, University Medical Center Freiburg, 79106 Freiburg, Germany.
A
A
Nieters
Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, 09124 Cagliari, Italy.
P
P
Cocco
1] Unit of Infections and Cancer, Cancer Epidemiology Research Programme, IDIBELL, Catalan Institute of Oncology, 08908 Barcelona, Spain [2] Department of Medicine, University of Barcelona, 08036 Barcelona, Spain [3] CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain.
S
S
de Sanjosé
D016022:Case-Control Studies; D052244:Endocrine Disruptors / Q000506:poisoning*; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D015994:Incidence; D008223:Lymphoma / Q000139:chemically induced / Q000453:epidemiology*; D008297:Male; D009784:Occupational Diseases / Q000139:chemically induced / Q000453:epidemiology*; D016273:Occupational Exposure / Q000009:adverse effects / Q000706:statistics & numerical data*; D012307:Risk Factors; D012737:Sex Factors
D052244:Endocrine Disruptors